MDL 19301 is a nonsteroidal anti-inflammatory agent with the following applications: inhibition of carrageenan-induced rat paw edema (ED₃₀ = 4.8 mg/kg); inhibition of Arthus reaction (ED₃₀ = 8.2 mg/kg p.o.); inhibition of carrageenan-induced pleurisy; suppression of adjuvant arthritis; reduction of HOAc-induced writhing; inhibition of prostaglandin synthesis; inhibition of arachidonic acid-induced diarrhea in mice (but not prostaglandin E₂-induced diarrhea); and inhibition of ex vivo arachidonic acid-induced rat platelet aggregation (but not ADP-induced aggregation). It exhibits a more favorable therapeutic ratio compared to conventional nonsteroidal anti-inflammatory agents, as evidenced by a gastric ulcerogenic dose (in 50% of fasted rats) greater than 1,000 mg/kg.